Pirbuterol Hydrochloride: Evaluation of Beta Adrenergic Agonist Activity in Reversible Obstructive Pulmonary Disease and Congestive Heart Failure

  title={Pirbuterol Hydrochloride: Evaluation of Beta Adrenergic Agonist Activity in Reversible Obstructive Pulmonary Disease and Congestive Heart Failure},
  author={Richard W. Weber and Harold S. Nelson},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  • R. Weber, H. Nelson
  • Published 2 January 1984
  • Medicine
  • Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Pirbuterol hydrochloride is a beta2 adrenergic agonist with a structure similar to that of albuterol, except for the substitution of a pyridine ring for the benzene ring. It is comparable in duration of action to albuterol when given by inhalation, but it is threefold less potent by weight. In man, pirbuterol and albuterol have similar beta2 selectivity. In the acute therapy of chronic obstructive pulmonary disease, pirbuterol is most effective in oral doses of 15–20 mg, and by aerosol in doses… Expand
7 Citations
Pirbuterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible bronchospastic disease.
Well-designed long term comparative studies are needed to more clearly define the comparative efficacy of pirbuterol and alternative beta-adrenoceptor agonists. Expand
Adverse Effects Associated with the Newer Inotropic Agents
A number of other non-catecholamine agents, most of which have both inotropic and vasodilator actions, have been studied but none has yet been proven in clinical trials to be safe and effective in the long term. Expand
Comparison of continuous sufentanil and fentanyl infusions for outpatient anaesthesia
It is concluded that the technique of continuous sufentanil infusion was superior to fentanyl in healthy outpatients undergoing D&C in healthy patients with ASA classe I or II. Expand
In vitro effects of ethanolamine on insulin secretion.
It is concluded that ethanolamine inhibits glucose-induced insulin secretion by the perfused rat pancreas and that alpha-adrenergic receptors play a role in its actions on insulin output. Expand
Asymmetric Hydroboration of Heteroaryl Ketones by Aluminum Catalysis.
Isolation and comprehensive characterization of the reaction intermediates support a catalysis cycle proposed by DFT calculations and the formed 2-heterocyclic-alcohols are valuable building blocks in drug discovery or can be used as ligands in asymmetric catalysis. Expand


Acute bronchial and cardiovascular effects of oral pirbuterol and metaproterenol.
Findings indicate that pirbuterol is an effective bronchodilator with a relatively long duration of action, definite beta 2-adrenergic specificity and insignificant toxicity when administered in a single dose. Expand
Pirbuterol: a new oral sympathomimetic amine for the treatment of congestive heart failure.
Pirbuterol orally has a marked and prolonged salutary hemodynamic effect and offers promise in CHF treatment and was clinically well tolerated. Expand
Comparison of hemodynamic actions of pirbuterol and dobutamine on cardiac function in severe congestive heart failure.
Oral pirbuterol has dobutamine-like beneficial hemodynamic effects on left ventricular pump function but causes a greater decrease in total systemic vascular resistance consistent with the combined inotropic and peripheral vasodilator actions of this oral beta adrenergic receptor agonist. Expand
Pirbuterol, a selecttve beta2 adrenergic bronchodilator.
Comparison of the relative potencies of pirbuterol, salbutamol and isoproterenol as relaxants of isolated guinea-pig tracheal muscle and as positive chronotropic agents in isolated Guinea-Pig atria indicate that the relative selectivity of pir buterol for pulmonary as opposed to cardiac tissue is 9 times greater than that for sal butamol. Expand
Hemodynamic Effects of Oral Pirbuterol in Chronic Severe Congestive Heart Failure
Oral pirbuterol provides beneficial hemodynamic effects in patients with severe left ventricular dysfunction and appears potentially useful for long-term management of low-output congestive heart failure. Expand
Effects of pirbuterol and sodium nitroprusside on pulmonary haemodynamics in hypoxic cor pulmonale
Pirbuterol acts as a vasodilator on the pulmonary circulation in patients with hypoxic chronic bronchitis and emphysema and may in addition improve right ventricular performance by an inotropic action. Expand
Acute Effects of Oral Pirbuterol on Myocardial Oxygen Metabolism and Systemic Hemodynamics in Chronic Congestive Heart Failure
Pirbuterol effects substantial acute hemodynamic improvement in patients with chronic congestive heart failure without increasing requirements for coronary blood flow or myocardial oxygen delivery and without provoking myocardIAL ischemia. Expand
Therapeutic efficacy or oral pirbuterol in severe chronic congestive heart failure: acute hemodynamic and long-term ambulatory evaluation.
Evaluated temporal cardiocirculatory responses to the new ingestible beta-adrenergic receptor agonist pirbuterol by cardiac catheterization and limb plethysmography in patients with coronary disease and severe CHF refractory to digitalis and diuretics found it to improve left ventricular dysfunction. Expand
Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol.
It is concluded that tolerance to the hemodynamic and clinical effects of pirbuterol develops during long-term administration; this tolerance may be related to a decrease in myocardial or vascular beta-adrenergic receptors or both. Expand
Treatment of chronic heart failure with pirbuterol: acute haemodynamic responses.
Oral pirbuterol clearly improved pump performance in patients with severe chronic heart failure, the haemodynamic changes being consistent with vasodilatation as the dominant mechanism rather than a direct inotropic effect. Expand